Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

MASH is a severe liver disease associated with obesity and ... of the skeletal muscle with the gene that encodes for the fibroblast growth factor 21 protein using adeno-associated viral vectors ...

Goldman Sachs & Co. LLC, Leerink Partners and BofA Securities are acting as lead book-running managers and Cantor is acting ...

such as the liver, lungs, and heart, become rigid or can result in autoimmune diseases such as scleroderma. Fibrosis occurs as fibroblasts differentiate into myofibroblasts. To control fibrosis ...